Sign Up Today and Learn More About Convergent Therapeutics Stock
Invest in or calculate the value of your shares in Convergent Therapeutics or other pre-IPO companies through EquityZen's platform.
Convergent Therapeutics Stock (COVT)
Convergent Therapeutics is a pharmaceutical company that focuses on developing radiopharmaceutical therapies for prostate cancer.
About Convergent Therapeutics Stock
Founded
2021
Headquarters
Cambridge, MA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Convergent Therapeutics Press Mentions
Stay in the know about the latest news on Convergent Therapeutics
Convergent Therapeutics Announces First Shipments of Actinium 225 from Cardinal Health to Support the CONVERGE-01 Phase 2 Clinical Trial
prnewswire • Nov 19, 2024
NorthStar, Convergent Therapeutics Expand Partnership
madisonstartups • Aug 15, 2024
Convergent Therapeutics Appoints Scott Myers as Chairman of its Board of Directors
prnewswire • Mar 04, 2024
Convergent Therapeutics Expands Leadership Team with the Appointments of Neil Bander, MD. as Chief Scientific ...
prnewswire • Mar 01, 2024
NextGen Class of 2024: Top Life Sciences Startups to Watch ...
biospace • Jan 19, 2024
Convergent Therapeutics Management
Leadership team at Convergent Therapeutics
Co-Founder & CEO
Philip Kantoff
Co-Founder
Neil Bander
Join now and verify your accreditation status to gain access to:
- Convergent Therapeutics current valuation
- Convergent Therapeutics stock price
- Available deals in Convergent Therapeutics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
Trading Convergent Therapeutics Stock
How to invest in Convergent Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Convergent Therapeutics through EquityZen funds. These investments are made available by existing Convergent Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Convergent Therapeutics stock?
Shareholders can sell their Convergent Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."